Wyeth
The deal was originally between Santaris and Wyeth, but Pfizer inherited the partnership when it acquired Wyeth late in 2009.
At the San Antonio Breast Cancer Symposium being held this week, Pfizer is planning to present new clinical trial data on neratinib, an investigational pan-ErbB inhibitor in patients with HER2-positive breast cancer, as well as data on the marketed oncologic Sutent (sunitinib malate) in metastatic breast cancer.
Alnylam’s request to stay the suit, which was submitted jointly with the USPTO, asked the court to suspend the case until a ruling is made on an appeal in a separate but similar patent-term suit filed by Wyeth and Elan Pharma against the patent office.
A Santaris official also said that while the company remains committed to microRNAs as drug targets, the company isn’t likely to advance additional miRNA drugs into the clinic in the near term as it takes a measured approach to selecting future clinical candidates.
Warren Bruggeman, Thomas Herzog, Lee Potts, Corey Goodman, Gregory Webb, Stephen Sands, Maggie Dias, Santiago Galvez, Elizabeth Goodman, Claudia Hillinger, Thad Seymour, Randy Scott, John Spencer, Thomas Stevens, Jim Talton, Daniel Wahby, Stephanie Warrington, Claudia Zylberberg
Apr 16, 2009
Mar 23, 2009
Mar 18, 2009
Feb 27, 2009
Feb 27, 2009
People in the News: Feb 27, 2009
Feb 26, 2009
Industry Briefs: Feb 26, 2009
Premium
Feb 24, 2009